LivaNova PLC $LIVN Stock Position Lessened by Primecap Management Co. CA

Primecap Management Co. CA lowered its stake in LivaNova PLC (NASDAQ:LIVN) by 4.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,444,832 shares of the company’s stock after selling 196,520 shares during the quarter. Primecap Management Co. CA owned about 8.14% of LivaNova worth $232,820,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Invesco Ltd. raised its position in shares of LivaNova by 714.7% during the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock worth $46,313,000 after buying an additional 902,447 shares in the last quarter. Scopia Capital Management LP bought a new stake in LivaNova during the second quarter worth approximately $36,657,000. Artisan Partners Limited Partnership lifted its position in LivaNova by 112.9% in the second quarter. Artisan Partners Limited Partnership now owns 1,247,609 shares of the company’s stock worth $56,167,000 after purchasing an additional 661,480 shares during the period. AQR Capital Management LLC boosted its stake in LivaNova by 30.5% during the 2nd quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock valued at $92,201,000 after purchasing an additional 478,525 shares in the last quarter. Finally, M&G PLC acquired a new position in shares of LivaNova during the 2nd quarter valued at $11,762,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

NASDAQ LIVN opened at $70.29 on Thursday. The company has a current ratio of 1.33, a quick ratio of 1.12 and a debt-to-equity ratio of 0.30. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $70.78. The company has a market cap of $3.84 billion, a PE ratio of -17.57 and a beta of 0.97. The stock’s 50-day moving average price is $64.41 and its two-hundred day moving average price is $58.81.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.80 by $0.06. LivaNova had a negative net margin of 16.12% and a positive return on equity of 15.98%. The business had revenue of $360.86 million during the quarter, compared to the consensus estimate of $354.31 million. During the same quarter in the prior year, the firm earned $0.81 EPS. The firm’s quarterly revenue was up 12.2% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. On average, analysts predict that LivaNova PLC will post 2.85 EPS for the current year.

Key Headlines Impacting LivaNova

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q4 results beat on both revenue and adjusted EPS; revenue was ~$360.9M (up ~12% y/y) and adjusted EPS topped consensus — management issued FY‑2026 adjusted EPS guidance of $4.15–$4.25, above Street estimates, which is the main near-term catalyst. Read More.
• Positive Sentiment: Analyst upgrade/price-target lift: Needham raised its price target to $81 and reiterated a Buy rating, reinforcing bullish sentiment following the results and guidance. Read More.
• Positive Sentiment: Short interest declined materially in February (down ~16.6% to ~2.03M shares), lowering potential downward pressure from short squeezes and signaling reduced bearish positioning into the earnings update.
• Neutral Sentiment: Management materials and the full earnings call transcript are available for deeper read-throughs (useful for assessing margin drivers and product/service momentum). Read More. · Read More.
• Neutral Sentiment: Market commentary is starting to assess longer-term drivers such as reimbursement gains and a new data partnership (Orrum) that could reshape cardiac-care positioning; these are potential catalysts but currently speculative. Read More. · Read More.
• Negative Sentiment: GAAP metrics and margins still show weaknesses: reported GAAP diluted EPS was lower than adjusted EPS and the company reported a negative net margin (~‑16%), suggesting non‑operating items or charges and that underlying profitability still needs improvement. Investors should monitor whether adjusted guidance is supported by sustained operating margin improvement. Read More.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d+)” rating on shares of LivaNova in a report on Monday, December 29th. KeyCorp assumed coverage on shares of LivaNova in a research report on Friday, December 19th. They issued an “overweight” rating and a $81.00 price target on the stock. Barclays raised their price objective on shares of LivaNova from $58.00 to $67.00 and gave the company an “equal weight” rating in a research report on Friday, January 9th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $66.00 target price on shares of LivaNova in a report on Friday, January 9th. Finally, Mizuho increased their target price on shares of LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $74.11.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.